Following the company’s fourth quarter results, Raymond James analyst Rahul Sarugaser has main... Read More
Raymond James analyst Rahul Sarugaser is feeling GUD about Knight Therapeutics (Knight Therapeutics ... Read More
Despite strong first quarter results, the growth runway for Canadian specialty pharma company Knight... Read More
Raymond James analyst David Novak is slightly clipping his estimate of Knight Therapeutics (Knight T... Read More
Stifel GMP Analyst Justin Keywood is still riding high with Knight Therapeutics (Knight Therapeutics... Read More
Paradigm Capital analyst Scott McAuley makes the case for investing in Canadian pharmaceutical compa... Read More
Biopharmaceutical stocks had their ups and downs over 2021 but volatility in the sector is par for t... Read More
Paradigm Capital Markets analyst Scott McAuley is still a fan of Knight Therapeutics (Knight Therap... Read More
Raymond James analyst David Novak is firmly behind Knight Therapeutics (Knight Therapeutics Stock Qu... Read More
Stifel GMP Analyst Justin Keywood is keying back in on Knight Therapeutics (Knight Therapeutics Stoc... Read More
It’s been literally years of waiting for Canadian specialty pharma company Knight Therapeutics (Kn... Read More
A new drug acquisition is cause for a target raise on Knight Therapeutics (Knight Therapeutics Stock... Read More
It’s still early innings for specialty pharma company Knight Therapeutics (Knight Therapeutics Sto... Read More
Stifel GMP analyst Justin Keywood says investors can expect to see Knight Therapeutics (Knight Thera... Read More
With most stocks well off their 12-month highs, there are plenty of potential wins in the market the... Read More
Stifel GMP analyst Justin Keywood likes what he sees so far from Knight Therapeutics (Knight Therape... Read More
Specialty pharma company Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News TSX:GUD) ... Read More
All’s well with Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News TSX:GUD) after t... Read More